Junctional Epidermolysis Bullosa

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ET
Eliksa TherapeuticsPA - Doylestown
1 program
1
ELK-003Phase 11 trial
Active Trials
NCT06713434Active Not RecruitingEst. Jun 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Eliksa TherapeuticsELK-003

Clinical Trials (1)

NCT06713434Eliksa TherapeuticsELK-003

Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa

Start: May 2024Est. completion: Jun 2026
Phase 1Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space